The Experts below are selected from a list of 44706 Experts worldwide ranked by ideXlab platform
John Nemunaitis - One of the best experts on this subject based on the ideXlab platform.
-
intrigue phase iii study of ripretinib versus sunitinib in advanced gastrointestinal Stromal Tumor after imatinib
Future Oncology, 2020Co-Authors: Margaret Von Mehren, John Nemunaitis, Sebastian Bauer, Jeanyves Blay, Khalil Choucair, Hans Gelderblom, Suzanne George, Patrick Schoffski, John ZalcbergAbstract:Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA. Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal Stromal Tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase inhibitors. Here we describe the rationale and design of intrigue (NCT03673501), a global, randomized (1:1), open-label, Phase III study comparing the safety and efficacy of ripretinib versus sunitinib in patients with advanced gastrointestinal Stromal Tumor following imatinib. The primary end point is progression-free survival and key secondary objectives include objective response rate and overall survival. Clinical Trial Registration: NCT03673501.
John Zalcberg - One of the best experts on this subject based on the ideXlab platform.
-
intrigue phase iii study of ripretinib versus sunitinib in advanced gastrointestinal Stromal Tumor after imatinib
Future Oncology, 2020Co-Authors: Margaret Von Mehren, John Nemunaitis, Sebastian Bauer, Jeanyves Blay, Khalil Choucair, Hans Gelderblom, Suzanne George, Patrick Schoffski, John ZalcbergAbstract:Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA. Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal Stromal Tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase inhibitors. Here we describe the rationale and design of intrigue (NCT03673501), a global, randomized (1:1), open-label, Phase III study comparing the safety and efficacy of ripretinib versus sunitinib in patients with advanced gastrointestinal Stromal Tumor following imatinib. The primary end point is progression-free survival and key secondary objectives include objective response rate and overall survival. Clinical Trial Registration: NCT03673501.
Kenichi Sugihara - One of the best experts on this subject based on the ideXlab platform.
-
intra abdominal desmoid Tumor after resection for gastrointestinal Stromal Tumor of the small intestine case report
Japanese Journal of Clinical Oncology, 2014Co-Authors: Hirotoshi Kobayashi, Kenichi SugiharaAbstract:Mesenchymal Tumors are thought to constitute only 1% of primary gastrointestinal malignancies. Both gastrointestinal Stromal Tumor and desmoid Tumor are rare. The case of a 56-year-old male with a desmoid Tumor 1 year after surgical removal of a gastrointestinal Stromal Tumor near the ligament of Treitz is described. Although he received adjuvant therapy of imatinib mesylate for 1 year after the surgery, a small nodule was found 1 year and 3 months after the surgery. The nodule was considered to be a recurrent Tumor of gastrointestinal Stromal Tumor, and a wedge resection of the duodenum including the Tumor was done. Histopathological examination by immunohistochemical staining revealed that it was a desmoid Tumor. It would be useful to be aware of the possibility of desmoid Tumor after removal of gastrointestinal Stromal Tumor. To accumulate further information on these rare diseases, a central database that includes rare diseases will be necessary.
Lei Li - One of the best experts on this subject based on the ideXlab platform.
-
sclerosing Stromal Tumor of the ovary in a 4 year old girl with characteristics of an ovarian signet ring Stromal Tumor
Pathology Research and Practice, 2010Co-Authors: Ying He, Kaixuan Yang, Wei Jiang, Danqing Wang, Lei LiAbstract:Ovarian sclerosing Stromal Tumor (OSST) is an extremely rare neoplasm that primarily affects young women. Signet-ring Stromal Tumor is another rare non-functioning benign ovarian Stromal neoplasm. We report a case of a right OSST with prominent characteristics of signet-ring Stromal Tumor in a 4-year-old girl with symptoms of premature thelarche. We describe the clinical, histopathological, and immunohistochemical findings and review the literature. To our knowledge, the 4-year-old patient presented here is the youngest case of OSST reported in premenarchal children. The presence of non-mucin/non-lipid obvious signet-ring-like cells in this case suggests a possible relationship between OSST and signet-ring Stromal Tumor of the ovary.
Iftiker Ahmad - One of the best experts on this subject based on the ideXlab platform.
-
jejunal gastrointestinal Stromal Tumor as a source of small bowel bleeding a case report
The Permanente Journal, 2021Co-Authors: Jacob Burch, Iftiker AhmadAbstract:Introduction In a minority of patients with gastrointestinal bleeding, the offending lesion is not able to be identified using colonoscopy or esophagogastroduodenoscopy (EGD). For these patients, video capsule endoscopy has become a cornerstone for the diagnosis of gastrointestinal bleeding in the territory not accessible by colonoscopy or EGD. One uncommon cause of bleeding from the small bowel is a gastrointestinal Stromal Tumor. Case presentation We present the case of a 76-year-old man who presented with 2 weeks of melena that began after starting dual antiplatelet therapy with aspirin and clopidogrel after undergoing coronary artery stenting. After EGD and colonoscopy failed to identify the culprit, the patient underwent video capsule endoscopy, which identified a suspicious area concerning for intussusception. Computed tomography enterography was then performed and showed a short segment of bowel wall thickening. The patient underwent laparoscopic small bowel resection and was found to have a gastrointestinal Stromal Tumor.
